Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lure Of Niche Drugs Lead India's Cadila To Buy Troubled KV Pharma's Generic Arm For $60 Million

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Troubled U.S. drug maker KV Pharmaceutical Co. met what it called "an important goal" managing to sell its generic drugs subsidiary Nesher Pharmaceuticals Inc. to one of India's fastest-growing generic drug makers Cadila Healthcare Ltd. Cadila's U.S. arm Zydus Pharmaceuticals Inc. facilitated its first buyout in the U.S. through its subsidiary Zynesher Pharmaceuticals USA LLC

You may also be interested in...



Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?

Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced April 1 it has cut the list price of its new preterm birth prevention drug Makena (hydroxyprogesterone caproate) by 54% – from $1,500 to $690 per injection – effective immediately.

Related Content

UsernamePublicRestriction

Register

SC078265

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel